Advertisement

Immuntherapeutika und Zytostatika

  • W. Jens Zeller

Zusammenfassung

Hauptgruppen der Immuntherapeutika sind Zytokine (Interferone, koloniestimulierende Faktoren) und Immunsuppressiva. Betainterferone werden in weiter steigendem Umfang zur Behandlung der multiplen Sklerose eingesetzt, Alfainterferone vor allem bei der Hepatitis C. Schwerpunkt der Immunsuppressiva ist die Prophylaxe von Abstoßungsreaktionen bei trans-plantierten Patienten.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Cancer Society (2002): Complementary and Alternative Cancer Methods Handbook. American Cancer Society.Google Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (1996): Wie verträglich sind Echinacea-haltige Präparate? Dtsch Ärztebl 93: A–2723.Google Scholar
  3. Beverly P (1995): Tumorimmunologie. In: Roitl JM, Broxtoff J, Male DK (Hrsg.): Kurzes Lehrbuch der Immunologie. 3. Aufl. Thieme, Stuttgart New York, S. 246–257.Google Scholar
  4. Brinkeborn RM, Shah DV, Degenring FH (1999): Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold. Phytomedicine 6: 1–5.PubMedCrossRefGoogle Scholar
  5. Collet JP, Shapiro S, Ernst P, Renzi P, Ducruet T, Robinson A, PARI-IS Study Steering Committee and Research Group (1997): Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 156:1719–1724.Google Scholar
  6. Dold U, Edler L, Mäurer HC et al. (1991): Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Thieme, Stuttgart.Google Scholar
  7. Dorsch W (1996): Klinische Anwendung von Extrakten aus Echinacea purpurea oder Echinacea pallida. Klinische Wertung kontrollierter klinischer Studien. Z Ärztl Fortbild (Jena) 90:117–122.Google Scholar
  8. Dunn CJ, Goa KL (2000): Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 59: 681–717.PubMedCrossRefGoogle Scholar
  9. Ernst E (2001a): A primer of complementary and alternative medicine commonly used by cancer patients. Med J Aust 174: 88–92.PubMedGoogle Scholar
  10. Ernst E (2001b): Mistletoe for cancer? Eur J Cancer 37: 9–11.PubMedCrossRefGoogle Scholar
  11. Ernst E (2001c): The desktop guide to complementary and alternative medicine an evidence-based approach. Mosby, Hartcourt.Google Scholar
  12. Fischer T (2002): Der Signalhemmer Imatinib Mesilat (STI571). Wirkprinzip und klinische Anwendung. UNI-MED, Bremen.Google Scholar
  13. Grimm W, Müller H-H (1999): A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 106:138–143.PubMedCrossRefGoogle Scholar
  14. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ (1990): Increased secretion of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 by human mono-nuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extracts. Cancer Res 50:3322–3326.PubMedGoogle Scholar
  15. Heiny BM, Albrecht V, Beuth J (1998): Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galac-tose-specific lectin standardized mistletoe extract. Anticancer Res 18: 583–586.PubMedGoogle Scholar
  16. Hohenberger P, Reichardt P, Stroszczynski C, Schneider U, Hossfeld DK (2003): Gastrointestinale Stromatumoren — Tumorentität und Therapie mit Imatinib. Dtsch Ärztebl 100: A1612–A1618.Google Scholar
  17. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. (1996): Intramuscular interferon β-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Colloborative Research Group (MSCRG). Ann Neurol 39:285–294.PubMedCrossRefGoogle Scholar
  18. Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K et al. for the Consensus Interferon Study Group (1999): Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Am J Gastroenterol 94: 3583–3588.PubMedCrossRefGoogle Scholar
  19. Kao JH, Chen PJ, Lai MY, Chen DS (2000): Efficacy of consensus interferon in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 15:1418–1423.PubMedCrossRefGoogle Scholar
  20. Kienle GS, Kiene H (2004): Klinische Studien zur Misteltherapie onkologischer Erkrankungen. Dtsch Zeitschr Onkol 36:17–24.Google Scholar
  21. Kienle GS, Kiene H (2003): Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Schattauer, Stuttgart.Google Scholar
  22. Kleijnen J, Knipschild P (1994): Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1: 255–260.PubMedCrossRefGoogle Scholar
  23. Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J (2000): Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20: 2073–2076.PubMedGoogle Scholar
  24. McHutchinson JG, Gordon SC, Schiff ER (1998): Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492.CrossRefGoogle Scholar
  25. Melchart D, Walther E, Linde K, Brandmaier R, Lersch C (1998): Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch Fam Med 7: 541–545.PubMedCrossRefGoogle Scholar
  26. Mullins RJ (1998): Echinacea-associated anaphylaxis. Med J Aust 16:170–171.Google Scholar
  27. Peggs K, Mackinnon S (2003): Imatinib Mesylate — The new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048–1050.PubMedCrossRefGoogle Scholar
  28. Pforte A, Emmerich B (1993): Störungen der Infektabwehr bei Patienten mit chronischer Bronchitis: präventive und supportive Möglichkeiten. Pneumologie 47: 395–402.PubMedGoogle Scholar
  29. Roitt IM, Brostoff J, Male DK (1991): Kurzes Lehrbuch der Immunologie. 2. Aufl., Thieme, Stuttgart, New York.Google Scholar
  30. Rote Liste 2004. Editio Cantor Verlag, Aulendorf.Google Scholar
  31. Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V (2001): Vorwort S.V. In: Scheer R. et al. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik, KVC, Essen.Google Scholar
  32. Stein G, Henn W, von Laue H, Berg P (1998): Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur J Med Res 3: 194–202.PubMedGoogle Scholar
  33. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J, Hennig M, Lenarz T, Arnold W (2001): The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37:23–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • W. Jens Zeller
    • 1
  1. 1.Deutsches KrebsforschungszentrumAbt. Perinatale ToxikologieHeidelberg

Personalised recommendations